NEWTON, Mass.–(BUSINESS WIRE)–Tryton Medical, Inc., the leading developer of stents designed to treat
bifurcation lesions, announced that it transmitted a live satellite feed
of a clinical case, which was performed at the Helios Heart Center in
Siegburg Germany, to an audience of over 1,000 interventional
cardiologists at the Joint Interventional Meeting (JIM 2007) in Rome.
The procedure was performed by Charles A. Simonton, III, M.D., FACC,
FSCAI, Director of Adult Cardiology Research at Carolinas Heart
Institute, in Charlotte, NC. “The Tryton Side-Branch Stent allowed us to
treat a difficult bifurcation lesion with a superb angiographic result,
through a 6-French guide, without interfering with my selection of a
stent for the main vessel. The final appearance of the side branch
origin was particularly impressive, I am not sure we could obtain such a
result without Tryton,” said Dr. Simonton.
“JIM 2007 provided an important informational venue, enabling 1,000
interventional cardiologists to review first-in-class devices, such as
the Tryton Side-Branch Stent, that will eventually provide a new
standard of care for problems they encounter every day,” said JIM 2007
Course Director and Co-chair, Professor Eberhard Grube, M.D.
“We were particularly pleased with the Siegburg, Germany case. The
audience was not aware that Dr. Simonton had not even seen a Tryton
Side-Branch Stent until 30 minutes before performing the procedure. The
routine nature of the case highlights how easily a Tryton Strategy can
be incorporated into the interventional armamentarium,” said H. Richard
Davis, CTO, Tryton Medical, Inc.
Every year, over half a million bifurcation coronary lesions are
sub-optimally treated as no commercially available optimized solution
exists for treating bifurcation lesions. As a result, cardiologists are
forced to use a provisional strategy which avoids the deployment of a
second stent– leaving the side branch vulnerable to thrombosis and
restenosis. “This technology has the capacity to redefine the treatment
of bifurcation lesions and resolve a frequent dilemma of the
interventional cardiologist,” said Professor Serruys, Head of the
Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical
Center, Rotterdam, Netherlands.
Unlike other stents and techniques used to treat bifurcation lesions,
Tryton’s stent is easy-to-deliver as it uses standard equipment and
techniques compatible with 5 French guiding catheters. Tryton greatly
facilitates patient treatment, as interventional cardiologists who use
the Side-Branch Stent will no longer have to worry about the bifurcation
as they will know the side-branch will stay open and, as a result, the
interventionalist is liberated to focus on the treatment of the main
vessel using their preferred choice of standard equipment.
About Tryton Medical, Inc.
Tryton Medical, Inc. is the leading developer of stents that are
designed to definitively treat bifurcation lesions. 540,000 bifurcation
coronary lesions are sub-optimally treated every year with a variety of
time consuming and technically challenging procedures. No optimized
solution is commercially available for treating bifurcation lesions. As
a result, cardiologists are forced to use a provisional strategy which
avoids the deployment of a second stent– leaving the un-stented side
branch vulnerable to thrombosis and restenosis. The ability to
definitively treat bifurcation lesions will enable PCI-stenting to
become the new standard of care for the treatment of left main coronary
artery disease rather than bypass surgery.
Tryton Medical’s Side-Branch Stent™ has all the characteristics of a
state-of the art workhorse stent, providing proven stent coverage to
bifurcation lesions while eliminating the need for provisional stenting.
For more information on Tryton Medical, Inc., contact Joe Romano,
Partner, HighGround, Inc. at +1 781-279-1320 x 208, jromano@highgroundinc.com
or visit trytonmedical.com